Abstract: Methods and compositions for treating cholangiocarcinoma.

Abstract: Methods and compositions for treating cholangiocarcinoma.

Abstract: Methods of treating a head and neck cancer are disclosed.

Abstract: Novel RET fusion molecules and uses are disclosed.

Abstract: Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

Abstract: Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.

Abstract: A system for tracking and analyzing cancer treatment and outcome information includes a user interface (UI) component for allowing selection of an alteration, an affected gene, an affected pathway, a tumor type, and/or a treatment; a processor configured to receive treatment information and outcome information associated with a patient population; organize the treatment information and the outcome information into at least one tuple; and generate outcome summary information; and an analysis component configured to compare a current patient record for a current patient to existing treatment information for the patient population, identify similar patients in the patient population based on information in the current patient record, and filter a grouping of similar patients; the processor is further configured to display, on the UI component, the outcome summary information; enable navigation within the treatment and outcome information; and identify, based on the outcome information, an appropriate treatment f

Abstract: Methods and compositions for treating a urothelial and/or a micropapillary carcinoma, such as a micropapillary urothelial carcinoma are disclosed.

Abstract: Methods of treating a head and neck cancer are disclosed.

Abstract: Various embodiments provide interfaces to access genomic testing information and incorporate it into daily physician practice. According to one aspect, a graph-based data model is used that may be used to organizes and revise precision medicine knowledge. In one example structure, gene states are abstracted into alteration groups, where alteration groups are built using reverse engineering actionable information and storing that information within the graph-based data structure. Volumes of genomic alterations and associated information (e.g., journal articles, clinical trial information, therapies, etc.) are analyzed and synthesized into actionable information items viewable on an alteration system in a graph-based data format. According to one embodiment, the system can be configured to focus practitioners on discrete portions of the alteration information on which they can act.

Abstract: Methods and compositions for treating cholangiocarcinoma.

Abstract: Methods of treating a head and neck cancer are disclosed.

Abstract: Methods and compositions for treating cholangiocarcinoma.

Abstract: Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

Abstract: Various embodiments provide interfaces to access genomic testing information and incorporate it into daily physician practice. In some embodiments, presentation of genomic alteration data is simplified and/or coupled with contextual applications. Volumes of genomic alterations and associated information (e.g., journal articles, clinical trial information, therapies, etc.) are analyzed and synthesized into actionable information items viewable on an alteration system. According to one embodiment, the system can be configured to focus practitioners on discrete portions of the alteration information on which they can act. According to other aspects, curated information is provided on the system to enable practitioners to make informed decisions regarding the implications of the presence of specific genomic alterations.

Abstract: Methods of treating a head and neck cancer are disclosed.

Abstract: A system for tracking and analyzing cancer treatment and outcome information includes a user interface (UI) component for allowing selection of an alteration, an affected gene, an affected pathway, a tumor type, and/or a treatment; a processor configured to receive treatment information and outcome information associated with a patient population; organize the treatment information and the outcome information into at least one tuple; and generate outcome summary information; and an analysis component configured to compare a current patient record for a current patient to existing treatment information for the patient population, identify similar patients in the patient population based on information in the current patient record, and filter a grouping of similar patients; the processor is further configured to display, on the UI component, the outcome summary information; enable navigation within the treatment and outcome information; and identify, based on the outcome information, an appropriate treatment f

Abstract: A system for managing genomic information includes a processor to collect and store biomarker data, receive and store patient-specific pathology information, generate a graph-based data structure of complex data elements arranged into a walkable graph representation that includes at least one of a disease alteration group association (DAGA) element representing a relationship between a disease and an alteration group (AG), at least one of a disease therapy association (DTA) element representing a relationship between a disease and a therapy for treating the disease, and a therapy genomic effect (TGE) element representing a relationship between a gene and a known effect of a therapy on the gene. The processor follows links in the walkable graph representation to determine at least one inferred path, generates inferential matches to actionable items based on an accumulated trust score of the at least one inferred path, and determines a treatment decision for a cancer patient.

Abstract: Methods of treating a head and neck cancer are disclosed.

Abstract: Novel RET fusion molecules and uses are disclosed.